We are live on ! Find out more
CATX icon

Perspective Therapeutics

26 hedge funds and large institutions have $10.5M invested in Perspective Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more capital invested

Capital invested by funds: $4.58M → $10.5M (+$5.9M)

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

4% more funds holding

Funds holding: 2526 (+1)

0.24% more ownership

Funds ownership: 0.38%0.62% (+0.24%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
4
Reduced
4
Closed
9
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q2 2014 in Review

26 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2014, worth a combined $10.5M — up 129% from $4.58M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CATX positions and 9 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Manatuck Hill Partners, opening a new position worth an estimated $1.5M. The largest seller was Sabby Management, exiting entirely with an estimated $496K sold.

  • 26 institutional investors held Perspective Therapeutics (CATX) as of Q2 2014, up from 25 in Q1 2014.
  • Funds reported $10.5M of Perspective Therapeutics stock for Q2 2014, up 129% quarter-over-quarter.
  • 10 funds opened new Perspective Therapeutics positions in Q2 2014 and 9 closed out, a net change of +1 holder.
  • The largest Perspective Therapeutics buyer in Q2 2014 was Manatuck Hill Partners, an estimated $1.5M added.
  • The largest Perspective Therapeutics seller in Q2 2014 was Sabby Management, an estimated $496K sold.

Based on aggregated 13F filings for Q2 2014.